Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with a market capitalization of $113 billion and "GREAT" financial health ...

In a separate Gilead briefing with journalists on Wednesday, Gilead Chief Financial Officer Andy Dickinson said Galapagos and Gilead came to the realization that Galapagos management was spending ...

Gilead stock has rallied some 40% since mid-June. CEO Daniel O’Day is fully convinced that governments, as well as private institutions, will line up funding for Gilead’s lenacapavir.

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $97.2 which represents a slight increase of $0.25 or 0.26% from the prior close of $96.95. The stock opened at $96.73 and ...

Gilead CFO Andy Dickinson offered his insights at JPM into why Big Pharma is increasingly making deals in China: 💡 Improved Innovation: Over the past five years, China has made significant ...

Porges also notes that the UK drugmaker’s interest in Gilead may suggest CEO Pascal Soriot wants to capitalise on its current position of strength “by making a large acquisition to diversify ...

Kampgrounds of America, Inc. (KOA), the largest system of privately owned campgrounds in the world, is proud to announce that ...